Syn2bio (WAR:S2B) EBITDA Margin %: 0.00% (As of Sep. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WAR:S2B Syn2bio SA WAR:S2B
11 GF Score
Price zł81.40
! 2 Warning Signs
View Full Analysis

What is Syn2bio EBITDA Margin %?

Syn2bio WAR:S2B +1.88% 11 EBITDA Margin % is 0.00% as of Sep. 2025. GuruFocus rates WAR:S2B with a GF Score™ of 11/100. The stock has 2 warning signs investors should review. Among 939 Biotechnology companies, Syn2bio ranks worse than 106496.17% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. Syn2bio's EBITDA for the six months ended in Sep. 2025 was zł-28.33 Mil. Syn2bio's Revenue for the six months ended in Sep. 2025 was zł0.00 Mil. Therefore, Syn2bio's EBITDA margin for the quarter that ended in Sep. 2025 was 0.00%.

Syn2bio  (WAR:S2B) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

Syn2bio EBITDA Margin % Related Terms

Syn2bio EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for Syn2bio's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Syn2bio EBITDA Margin % Chart

Syn2bio Annual Data
Trend Sep23 Sep24 Sep25
EBITDA Margin %
0.00 0.00 0.00

Syn2bio Semi-Annual Data
Sep23 Sep24 Sep25
EBITDA Margin % 0.00 0.00 0.00

WAR:S2B vs VRTX, REGN, ALNY: EBITDA Margin % Comparison

For the Biotechnology subindustry, Syn2bio's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Syn2bio EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Syn2bio's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where Syn2bio's EBITDA Margin % falls into.


WAR:S2B
11GF Score
Syn2bio SA WAR:S2B
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Syn2bio EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

Syn2bio's EBITDA Margin % for the fiscal year that ended in Sep. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Sep. 2025 )/Revenue (A: Sep. 2025 )
=-28.329/0
= %

Syn2bio's EBITDA Margin % for the quarter that ended in Sep. 2025 is calculated as

EBITDA Margin %=EBITDA (Q: Sep. 2025 )/Revenue (Q: Sep. 2025 )
=-28.329/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of 0.00% mean?
Syn2bio (WAR:S2B) has a EBITDA Margin % of 0.00% as of Sep. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Syn2bio and its competitors. According to the industry distribution chart, Syn2bio ranks #999999 out of 939 companies in the Biotechnology industry.
Is Syn2bio's EBITDA Margin % too high?
Syn2bio's current EBITDA Margin % is 0.00%. Based on the distribution chart, Syn2bio ranks #999999 out of 939 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Syn2bio has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Syn2bio's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Syn2bio ranks #999999 out of 939 companies for EBITDA Margin %. This places Syn2bio in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Syn2bio and its competitors. Syn2bio's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Syn2bio stock overvalued right now?
Syn2bio (WAR:S2B) has a current EBITDA Margin % of 0.00%. The current EBITDA Margin % is 0.00%. Syn2bio's overall GF Score™ is 11/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Syn2bio (WAR:S2B), the current EBITDA Margin % is 0.00% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Syn2bio Business Description

Address ul. Jozefa Piusa Dziekonskiego 3, Warszawa, POL, 00-728
Syn2bio SA is a Polish biotech company that develops radiopharmaceuticals. It specializes in developing a cardiac biomarker for diagnosing heart conditions like coronary artery disease through myocardial perfusion imaging. The company's flagship product is the SYN2 cardiotracer. It is applied in the detection of perfusion disorders, evaluation of patients after myocardial infarction or with ischemic heart disease, and assessment of atherosclerotic changes in coronary arteries.
11GF Score

Get the complete analysis for WAR:S2B

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł81.40
Price